Name:Yang Gong 
Department: Cancer Institute

Education & Professional Experience   Dr. Yang received his Ph.D. degree in 2001 from Institute of Microbiology, Chinese Academy of Sciences. He then pursued his research career in USA and worked in Rice University, The University of Texas MD Anderson Cancer Center as a postdoctoral fellow, Instructor, and Assistant Professor from 2001 to 2010. He was recruited as an independent Principle Investigator (PI)/Professor in Fudan University Shanghai Cancer Center, and now is majoring in translational cancer research.
Specialty   Gynecological Oncology, Cancer Biology, Molecular Oncology
Research   Dr. Yang’s work is mainly focused on cellular immortalization and senescence, tumor microenvironment, identification of cancer biomarkers, cancer recurrence and metastasis, chemo- and radioresistance of ovarian cancer, cervical cancer, breast cancer, etc. He has strong publications in top cancer research journals including Journal of National Cancer Institute, Cancer Research, Oncogene, Clinical Cancer Research, Oncotarget, Molecular Cancer, BBA (Molecular Cell Research), International Journal of Cancer, European Journal of Cancer, Journal of Biological Chemistry.
Publication   1.Sun JM, Yang LN, Xu H, Chang B, Wang HY, Yang G**. Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells. Am J Cancer Res 2015; 5(3):1133-1145.
2.Hou J, Wang Z, Xu H, Yang L, Yu X, Yang Z, Deng Y, Meng J, Feng Y, Guo X, Yang G**. Stanniocalicin 2 Suppresses Breast Cancer Cell Migration and Invasion via the PKC/Claudin-1-Mediated Signaling. PLoS One. 2015 Apr 1;10(4):e0122179. doi: 10.1371/journal.pone.0122179. e Collection 2015.
3.Yang L, Shi T, Liu F, Ren C, Wang Z, Li Y, Tu X, Yang G**, Cheng X. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells. PLoS One. 2015 Mar 17;10(3):e0120334. doi: 10.1371/journal.pone.0120334. eCollection 2015.
4.Wang Z, Liu Y, Lu L, Yang L, Yin S, Wang Y, Qi Z, Meng J, Zang R, Yang G**.
Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis. Oncotarget. 2015 Mar 30;6(9):6670-83.
5.Yang L, Zhou Y, Wu Y, Cui Y, Yang G**, and Hong Y. p53 deficiency and KRAS mutation synergistically activate NF-kB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells. Cancer Lett. 2015 Feb 28;357(2):520-6. doi: 0.1016/j.canlet.2014. 12.003. Epub 2014 Dec 8.
6.Wang Z, Liu Y, Yang L, Yin S, Zang R, Yang G**. The polymorphism interleukin-8 -251A/T is associated with a significantly increased risk of cancers from a meta-analysis. Tumour Biol. 2014 Jul;35(7):7115-23. doi: 10.1007/s13277-014- 1881-5. Epub 2014 Apr 24.
7.Qian Y, Wang Y, Ji Q, Yang G**. The chemokine receptor- CXCR2 plays a critical role in the invasion and metastasis of oral squamous cell carcinoma in vitro and in vivo. J Oral Pathol Med. 2014 Jun 23. doi: 10.1111/jop.12189. [Epub ahead of print].
8.Hou J, Wang Z, Yang L, Guo X, Yang G**. The function of EMSY in cancer development. Tumour Biol. 2014 Jun;35(6):5061-6. doi: 10.1007/s13277-013-1584-3. Epub 2014 Mar 9.
9.Wang Y, Wang Z, Qi Z, Yin S, Zhang N, Liu Y, Liu M, Meng J, Zang R, Zhang Z, Yang G**. The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy. Mol Cancer. 2014 Apr 28;13:94. doi: 10.1186/1476-4598 -13-94.
10.Sun H, Wang Y, Wang Z, Meng J, Qi Z, Yang G**. Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks. Biochim Biophys Acta (Molecular Cell Research). 2014 Jan 28. pii: S0167-4889(14)00031-7. doi: 10.1016/j.bbamcr.2014.01.019. [Epub ahead of print]
11.Wang Y, Sun H, Wang Z, Liu M, Qi Z, Meng J, Sun J, Yang G**. Aurora-A: a potential DNA repair modulator. Tumour Biol. 2014 Apr;35(4):2831-6. doi: 10.1007/s13277-013-1393-8. Epub 2013 Nov 26.
12.Wang Z, Hou J, Lu L, Qi Z, Sun J, Gao W, Meng J, Wang Y, Sun H, Gu H, Xin Y, Guo X, Yang G**. Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K/AKT and MAPK pathways. PLoS One. 2013 Nov 11;8(11):e79117. doi: 10.1371/journal. pone.0079117. eCollection 2013.
13.Chen Y, Ke G, Han D, Liang S, Yang G, Wu X. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD. Exp Cell Res. 2014 Jan 1;320(1):12-20. doi: 10.1016/j.yexcr.2013.10.014. Epub 2013 Oct 31.
14.Ren C, Cheng X, Lu B, Yang G**. Activation of interleukin-6/signal transducer and activator of transcription 3 by human papillomavirus early proteins 6 induces fibroblast senescence to promote cervical tumourigenesis through autocrine and paracrine pathways in tumour microenvironment. Eur J Cancer. 2013 Dec;49(18):3889-99. doi: 10.1016/j.ejca.2013.07.140. Epub 2013 Aug 15.
15.Lin F, Luo J, Gao W, Wu J, Shao Z, Wang Z, Meng J, Ou Z, Yang G**. COX-2 promotes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasiveness. Tumour Biol. 2013 Oct;34(5):2817-26. doi: 10.1007/s13277-013-0840-x. Epub 2013 Jun 15.
16.Yang G**, Mercado-Uribe I, Multani AS, Sen S, Shih IM, Wong KK, Gershenson DM, Liu J. RAS Promotes Tumorigenesis through Genomic Instability Induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis. Int J Cancer. 2013 Jul 15;133(2):275-285.
17.Shi TY, Yang L, Yang G, Tu XY, Wu X, Cheng X, Wei Q. DNA polymerase ζ as a potential biomarker of chemoradiation resistance and poor prognosis for cervical cancer. Med Oncol. 2013 Jun;30(2):500.
18.Shi TY, Yang G, Tu XY, Yang JM, Qian J, Wu XH, Zhou XY, Cheng X, Wei Q. RAD52 variants predict platinum resistance and prognosis of cervical cancer.PLoS One. 2012;7(11):e50461.
19.Guo X, Liu G, Schauer, IG, Yang G, Mercado-Uribe,I, Yang F, Zhang,S, He Y, Liu J, Over-expression of the beta subunit of human chorionic gonadotropin promotes the transformation of human ovarian epithelial cells and ovarian tumorigenesis. Am J Pathol. 2011 Sep;179(3): 1385-93.
20.Yang F, Guo X, Yang G, Rosen DG and Liu J. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma. Modern Pathology. 2011 Mar 25.
21.Yang G, Xiao X, Rosen DG, Cheng X, Wu X, Chang B, Liu G, Xue F, Mercado- Uribe I, Chiao PJ, Du X, Liu J. The Biphasic Role of NF-{kappa}B in Tumor Progression and Chemoresistance of Ovarian Cancer. Clin Cancer Res. 2011 Apr 15;17(8):2181-94.
22.Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, Liu J, Kavanagh JJ. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol. 2011 May 1;121(2):323-7.
23.Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res. 2010 Aug 1;16(15):3875-86.
24.Liu G, Yang G*, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J. Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst. 2010 Jun 2;102(11):812-27. (*co-first author)
25.Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S, Multani AS, Mercado-Uribe I, Liu J. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res. 2010 Jun 15;16(12):3171-81.
26.Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Noara H, Auersperg N, Mills GB, Bast RC, Liu J. Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle. 2010, Jan 1;9(1):140-6.
27.Xiao X, Bai P, Bui Nguyen TM, Xiao J, Liu S, Yang G, Hu L, Chen X, Zhang X, Liu J, Wang H. The antitumoral effect of Paris Saponin I associated with the induction of apoptosis through the mitochondrial pathway. Mol Cancer Ther. 2009 May 12.
28.Shan W, Yang G, Liu J . The inflammatory network: bridging senescent stroma and epithelial tumorigenesis. Front Biosci. 2009 Jan 1;14:4044-57.
29.Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, Zheng J, Xue FX, Liu J. Ovarian cancer: pathology, biology, and disease models. Front Biosci. 2009 Jan 1;14:2089-102
30.Chang B, Liu G, Yang G, Mercado-Uribe I, Huang M, Liu J. REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Cell Cycle. 2009 Mar 1;8(5):780-6. Epub 2009 Mar 20.
31.Wang D, Zhao Z, Caperell-Grant A, Yang G, Mok SC, Liu J, Bigsby RM, Xu Y. S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Mol Cancer Ther. 2008 Jul;7 (7):1993-2002.
32.Zhang Z, Singh M, Davidson S, Rosen DG, Yang G, Liu J. Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries. Mod Pathol. 2007 Oct; 20(10):1078-84.
33.Yang G, Rosen DG, Colacino JA, Mercado-Uribe I, Liu J. Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase lead to immortalization of human ovarian surface epithelial cells. Oncogene. 2007 Mar 1; 26(10): 1492-8.
34.Young TW, Mei FC, Rosen DG, Yang G, Li N, Liu J, Cheng X. Up-regulation of Tumor Susceptibility Gene 101 Protein in Ovarian Carcinomas Revealed by Proteomics Analyses. Mol Cell Proteomics. 2007 Feb; 6(2): 294-304.
35.Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC Jr, Zhou C, Liu J. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis. 2007 Jan; 28(1): 174-82.
36.Rosen DG, Mercado-Uribe I, Yang G, Bast RC Jr, Amin HM, Lai R, Liu J. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer. 2006 Dec 1; 107(11): 2730-40.
37.Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC Jr, Le XF. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene. 2006 Nov 2; 25(52): 6986-96.
38.Yang G, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, Colacino JA, Mercado-Uribe I, Liu J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A. 2006 Oct 31; 103(44): 16472-7.
39.Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, Liu J. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer. 2006 May 1; 106(9): 1925-32.
40.Rosen DG, Yang G*, Bast RC Jr, Liu J. Use of ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. Methods Enzymol. 2005; 407: 660-76. (*co-first author)
41.Hu Y, Rosen DG, Zhou Y, Feng L, Yang G, Liu J, Huang P. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem. 2005 Nov 25; 280(47): 39485-92.
42.Rosen DG, Yang G, Cai KQ, Bast RC Jr, Gershenson DM, Silva EG, Liu J. Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1): 632-7.
43.Young TW, Mei FC, Yang G, Thompson-Lanza JA, Liu J, Cheng X. Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res. 2004 Jul 1; 64(13): 4577-84.
44.Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, Bast RC Jr. A genetically defined model for human ovarian cancer. Cancer Res. 2004 Mar 1; 64(5): 1655-63.
45.Ehrenman K, Yang G, Hong WP, Gao T, Jang W, Brock DA, Hatton RD, Shoemaker JD, Gomer RH. Disruption of aldehyde reductase increases group size in dictyostelium. J Biol Chem. 2004 Jan 9; 279(2): 837-47.
46.Yang G, Cai KQ, Thompson-Lanza JA, Bast RC Jr, Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem. 2004 Feb 6; 279(6): 4339-45.
Yang G, Thompson JA, Fang B, Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer. Oncogene. 2003 Aug 28; 22(36): 5694-701.